Strong progress on innovation across divisionsPharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and CART with immuno-oncology assetsAlcon is focused on eye …
Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosisSandoz has begun shipping to US customers following recent FDA approvalNovartis and Sandoz are driving access to a …
Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosisSandoz has begun shipping to US customers following recent FDA approvalNovartis and Sandoz are driving access to a …
Princeton, New Jersey, June 4, 2015 – Sandoz today announced the US market introduction of guanfacine hydrochloride extended release tablets, a generic version of INTUNIV®, which is currently marketed by Shire Pharmaceuticals.Guanfacine hydrochloride e…
Princeton, New Jersey, June 4, 2015 – Sandoz today announced the US market introduction of guanfacine hydrochloride extended release tablets, a generic version of INTUNIV®, which is currently marketed by Shire Pharmaceuticals.Guanfacine hydrochloride e…
Stryków, May 07, 2015 – Sandoz, the generic Division of Novartis is announcing today the opening of the Sandoz Packaging Centre in Stryków – a project valued at 171 million PLN. It is one of the largest investment projects in the Polish pharmaceutical …
Stryków, May 07, 2015 – Sandoz, the generic Division of Novartis is announcing today the opening of the Sandoz Packaging Centre in Stryków – a project valued at 171 million PLN. It is one of the largest investment projects in the Polish pharmaceutical …
Basel, April 23, 2015 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Our focus on execution has resulted in a strong operational performance. We have completed the GSK and Lilly transactions and innovation continues to be strong. …
Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosisNovartis and Sandoz are driving access to a full range of differentiated, high-quality MS therapeutic options, comp…
April 16, 2015 – AirFluSal® Forspiro®, an innovative respiratory inhaler from Sandoz, has won the coveted Alufoil Trophy 2015 in the Product Preservation category. The inhaler uses a specially designed alufoil blister strip, which was developed by Amco…